Secukinumab Therapy in Psoriasis Management
Downloads
Background : In recent years, use of biological therapy in psoriasis has increased as a result of advances in understanding the pathophysiology of psoriasis disease. Biological agents currently approved for the treatment of moderate to severe plaque psoriasis including inhibitor TNF-α (adalimumab, etanercept, infliximab), inhibitor IL-17 (ixekizumab, brodalumab, secukinumab), inhibitor IL-12/IL-23 (ustekinumab), and inhibitor IL-23 (guselkumab, tildrakizumab). Secukinumab is a human monoclonal antibody that selectively neutralizes IL-17A, a cytokine involved in the development of psoriasis. Review: Psoriasis is a chronic skin inflammation with the characteristic form of erythematous plaque firmly, thick scale, layered, and silvery-white. The trigger factors cause damage to the skin and produce cytokines IFN-γ, TNF-α, IL-17, and IL-22. This proinflammatory cytokine induces the proliferation of keratinocytes and subsequently causes skin inflammation, leading to plaque psoriasis formation. Biologic agents are utilized to block those cytokines. There are three main classes of biological agents in the treatment of psoriasis: inhibitor TNFα, inhibitor IL-17, and inhibitor IL-23. Secukinumab is a fully human antibody that selectively binds and neutralizes IL-17A. Conclusion: Biological agents targeting IL-17 receptors are more effective and safer than biological agents that target TNF-α and IL-23 receptors for moderate to severe plaque psoriasis treatment. Secukinumab has been approved for plaque psoriasis therapy in adults, psoriasis arthritis (PsA), and ankylosing spondylitis.
Thaçi D, Körber A, von Kiedrowski R, Bachhuber T, Melzer N, Kasparek T, et al. Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study. J Eur Acad Dermatology Venereol. 2020;34(2):310–8.
Reszke R, Szepietowski JC. Secukinumab in the treatment of psoriasis: an update. Immunotherapy. 2017;9(3):229–38.
Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz I Bin, Kurtzman DJB. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat. 2018;29(6):569–78.
Gudjonsson, Johan E, Elder J. Psoriasis. In: Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A LD, editors. Fitzpatricks Dermatology in General Medicine. 2019. p. 491–531.
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatology Venereol. 2017;31(2):205–12.
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1–28.
Frischknecht L, Vecellio M, Selmi C. The role of epigenetics and immunological imbalance in the etiopathogenesis of psoriasis and psoriatic arthritis. Ther Adv Musculoskelet Dis. 2019;11(Il):1–8.
Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–94.
Schleicher SM. Psoriasis: pathogenesis, assessment, and therapeutic update. Clin Podiatr Med Surg. 2016;33(3):355–66.
Bozek A, Reich A. The reliability of three psoriasis assessment tools: psoriasis area and severity index, body surface area and physician global assessment. Adv Clin Exp Med. 2017;26(5):851–6.
Gisondi P, Del Giglio M, Girolomoni G. Treatment approaches tomoderate to severe psoriasis. Int J Mol Sci. 2017;18(11).
Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.
Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201.
Walsh JA, Jones H, Mallbris L, Callis Duffin K, Krueger GG, Clegg DO, et al. The physician global assessment and body surface area composite tool is a simple alternative to the psoriasis area and severity index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA. Psoriasis: Targets and Ther. 2018;8:65–74.
Smith CH, Jabbar-Lopez ZK, Yiu ZZ, Bale T, Burden AD, Coates LC, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177(3):628–36.
Eldirany SA, Ho M, Bunick CG. Structural basis for how biologic medicines bind their targets in psoriasis therapy. Yale J Biol Med. 2020;93(1):19–27.
Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11).
Kofoed K, Skov L, Zachariae C. New drugs and treatment targets in psoriasis. Acta Derm Venereol. 2015;95(2):133–9.
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–46.
Shirley M, Scott LJ. Secukinumab: a review in psoriatic arthritis. Drugs. 2016;76(11):1135–45.
Nast A, Spuls PI, van der Kraaij G, Gisondi P, Paul C, Ormerod AD, et al. European S3-guideline on the systemic treatment of psoriasis vulgaris – update apremilast and secukinumab – EDF in cooperation with EADV and IPC. J Eur Acad Dermatology Venereol. 2017;31(12):1951–63.
Cada DJ, Baker DE, Panther SG, Ingram K. Secukinumab. Hosp Pharm. 2015;50(8):714–27.
Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia. Alur tata laksana psoriasis tipe plak di Indonesia. 2019. Jakarta: Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia
Mrowietz U, Leonardi CL, Girolomoni G, Toth D, Morita A, Balki SA, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27-36.e1.
Gisondi P, Rovaris M, Piaserico S, Girolomoni G. Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. Br J Dermatol. 2020;182(1):175–9.
Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, et al. Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. J Am Acad Dermatol. 2017;76(4):655–61.
Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–9.
Cai L, Zhang J, Yao X, Gu J, Liu Q, Zheng M, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis. Chinese Medical Journal. 2020;133(22):2665-2673.
Lee J-H, Morita A, Tsai T-F, Zheng E, Ko L, Fox T, et al. Secukinumab efficacy and safety in Asian subjects with moderate to severe plaque psoriasis: Pooled analysis from the FIXTURE and ERASURE phase III clinical studies. Journal Of The American Academy Of Dermatology. 2015;72(5):AB249.
Nopriyati & Maradong R. Secukinumab for Psoriasis Treatment: A Case Series. Proceedings Of The 23Rd Regional Conference Of Dermatology. 2018. p. 496-499.
- Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
- The legal formal aspect of journal publication accessibility refers to Creative Commons Atribusi-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
- The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.
